急性髓系白血病细胞诱导分化后 STC-1基因表达的变化研究
摘要
关键词
全文:
PDF参考
Ballman, K.V. Biomarker: Predictive or prognostic? J. Clin. Oncol. 2015, 33, 3968–3971.
Gerstung, M.; Papaemmanuil, E.; Martincorena, I.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Heuser, M.; Thol, F.;Bolli, N.; Ganly, P.; et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach.Nat. Genet. 2017, 49, 332–340.
Dǒhner, K.; Paschka, P. Intermediate-risk acute myeloid leukemia therapy: Current and future. Hematol. Am.Soc. Hematol. Educ. Progr. 2014, 2014, 34–43.
Ossenkoppele, G.; Schuurhuis, G.J. MRD in AML: Does it already guide therapy decision-making? Hematol.Am. Soc. Hematol. Educ. Progr. 2016, 2016, 356–365.
Grimwade, D.; Freeman, S.D. Defining minimal residual disease in acute myeloid leukemia: Which platforms are ready for “prime time”Blood 2014, 124, 3345–3355.
Messina, C.; Candoni, A.; Carrabba, M.G.; Tresoldi, C.; Sala, E.; Tassara, M.; Crippa, A.; Peccatori, J.;Assanelli, A.; Gattillo, S.; et al. Wilms’ tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.Biol. Blood.Marrow Transplant. 2014, 20, 1586–1591.
DOI: https://doi.org/10.36012/pmr.v2i4.2713
Refbacks
- 当前没有refback。